Meibomian Gland Dysfunction (MGD)
6
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
17%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (6)
Effectiveness of Low Level Light Therapy and Intense Pulse Light on Mite Count as Adjuntive Therapies in Demodex Blepharitis Using Artificial Intelligent Program (Ai-Demodex)
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
The Effect of an Eyelid Warming Device for the Management of Meibomian Gland Dysfunction
Treatment of Meibomian Gland Dysfunction